Literature DB >> 32043440

Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.

Carvel Suprien1, Paulo N Rocha2,1, Marina Teixeira3, Lucas P Carvalho4,1,2,5,6, Luiz H Guimarães7,6, Toby Bonvoisin8, Paulo R L Machado6,2, Edgar M Carvalho2,6,5.   

Abstract

Cutaneous leishmaniasis (CL) caused by Leishmania braziliensis occurs predominantly in adult males. Herein, we compare the clinical presentation and the response to antimony therapy of CL in children versus adults. Participants included 571 patients with CL; of these, 129 were children (age ≤ 12 years). Cure was defined as the complete healing of ulcer in the absence of raised borders at day 90 after initiation of therapy. Failure was defined by the presence of an active ulcer or a scar with elevated borders at day 90. In comparison with adults, children had shorter duration of illness, more lesions in the head, and smaller ulcers. Risk factors for therapeutic failure were younger age, shorter duration of disease, higher number of lesions, and larger size of the biggest ulcer. When age was categorized in ≤ 12-year-olds (children versus adults), it predicted therapeutic failure with statistical significance at day 60 but not at day 90. In conclusion, our data indicate that there are significant differences in the clinical presentation of CL between children and adults. Physicians caring for children with CL should be aware that lesions may take longer to heal and remain alert for the possibility of higher odds of therapeutic failure in this group.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32043440      PMCID: PMC7124913          DOI: 10.4269/ajtmh.19-0531

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  36 in total

1.  Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.

Authors:  G A Romero; M V Guerra; M G Paes; V O Macêdo
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

2.  Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period.

Authors:  Lara Jirmanus; Marshall J Glesby; Luiz H Guimarães; Ednaldo Lago; Maria Elisa Rosa; Paulo R Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

3.  Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B.

Authors:  Paulo R L Machado; Maria Elisa A Rosa; Luís H Guimarães; Fernanda V O Prates; Adriano Queiroz; Albert Schriefer; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2015-06-05       Impact factor: 9.079

4.  Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients.

Authors:  Silvana C Silva; Luiz Henrique Guimarães; Juliana A Silva; Viviane Magalhães; Lilian Medina; Adriano Queiroz; Paulo Roberto L Machado; Albert Schriefer
Journal:  Acta Trop       Date:  2017-10-16       Impact factor: 3.112

Review 5.  American cutaneous leishmaniasis in infancy and childhood.

Authors:  Alberto E Paniz-Mondolfi; Carolina Talhari; María F García Bustos; Tamara Rosales; Wilmer E Villamil-Gomez; Marilianna Marquez; Alexandra M Pérez Alvarez; Alejandra I Tálamo Sánchez; Alfonso J Rodriguez-Morales
Journal:  Int J Dermatol       Date:  2017-07-25       Impact factor: 2.736

6.  Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.

Authors:  Adriana Cruz; Petrie M Rainey; Barbara L Herwaldt; Grazia Stagni; Ricardo Palacios; Rodolfo Trujillo; Nancy G Saravia
Journal:  J Infect Dis       Date:  2007-01-11       Impact factor: 5.226

7.  Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

Authors:  Alejandro Llanos-Cuentas; Gianfranco Tulliano; Roger Araujo-Castillo; Cesar Miranda-Verastegui; Giovanna Santamaria-Castrellon; Luis Ramirez; Marcela Lazo; Simonne De Doncker; Marleen Boelaert; Jo Robays; Jean-Claude Dujardin; Jorge Arevalo; Francois Chappuis
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.

Authors:  Paulo R Machado; Julia Ampuero; Luiz H Guimarães; Leonardo Villasboas; Ana T Rocha; Albert Schriefer; Rosana S Sousa; Anette Talhari; Gerson Penna; Edgar M Carvalho
Journal:  PLoS Negl Trop Dis       Date:  2010-12-21

9.  Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions.

Authors:  Cristian Valencia; Jorge Arévalo; Jean Claude Dujardin; Alejandro Llanos-Cuentas; François Chappuis; Mirko Zimic
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

Review 10.  Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.

Authors:  Ludovic Reveiz; Ana Nilce Silveira Maia-Elkhoury; Rubén Santiago Nicholls; Gustavo Adolfo Sierra Romero; Zaida E Yadon
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

View more
  1 in total

1.  Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis.

Authors:  Tainã Lago; Lucas P Carvalho; Mauricio Nascimento; Luiz H Guimarães; Jamile Lago; Léa Castellucci; Augusto M Carvalho; Alex Lago; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.